journal
MENU ▼
Read by QxMD icon Read
search

Journal of Hematology & Oncology

journal
https://www.readbyqxmd.com/read/29132432/ac-93253-iodide-a-novel-src-inhibitor-suppresses-nsclc-progression-by-modulating-multiple-src-related-signaling-pathways
#1
Yi-Hua Lai, Sih-Yin Lin, Yu-Shan Wu, Huei-Wen Chen, Jeremy J W Chen
BACKGROUND: The tyrosine kinase Src is involved in the progression of many cancers. Moreover, inhibiting Src activity has been shown to obstruct several signaling pathways regulated by the EGFR. Thus, Src is a valuable target molecule in drug development. The purpose of this study was to identify compounds that directly or indirectly modulate Src to suppress lung cancer cell growth and motility and to investigate the molecular mechanisms underlying the effects of these compounds. METHODS: Human non-small cell lung cancer (NSCLC) cell lines (PC9, PC9/gef, A549, and H1975) with different EGFR statuses were tested by cytotoxicity and proliferation assays after AC-93253 iodide treatment...
November 13, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29132397/kinase-profiling-of-liposarcomas-using-rnai-and-drug-screening-assays-identified-druggable-targets
#2
Deepika Kanojia, Manoj Garg, Jacqueline Martinez, Anand M T, Samuel B Luty, Ngan B Doan, Jonathan W Said, Charles Forscher, Jeffrey W Tyner, H Phillip Koeffler
BACKGROUND: Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease. The Achilles heel of cancer often is their kinases that are excellent therapeutic targets. However, very limited knowledge exists of therapeutic critical kinase targets in liposarcoma that could be potentially used in disease management. METHODS: Large RNAi and small-molecule tyrosine kinase inhibitor screens were performed against the proliferative capacity of liposarcoma cell lines of different subtypes...
November 13, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29096668/observational-study-of-lenalidomide-in-patients-with-mantle-cell-lymphoma-who-relapsed-progressed-after-or-were-refractory-intolerant-to-ibrutinib-mcl-004
#3
Michael Wang, Stephen J Schuster, Tycel Phillips, Izidore S Lossos, Andre Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Peter Martin
BACKGROUND: The observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance. METHODS: The primary endpoint was investigator-assessed overall response rate based on the 2007 International Working Group criteria. RESULTS: Of 58 enrolled patients (median age, 71 years; range, 50-89), 13 received lenalidomide monotherapy, 11 lenalidomide plus rituximab, and 34 lenalidomide plus other treatment...
November 2, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29084594/role-of-ap-2%C3%AE-and-mapk7-in-the-regulation-of-autocrine-tgf-%C3%AE-mir-200b-signals-to-maintain-epithelial-mesenchymal-transition-in-cholangiocarcinoma
#4
Dawei Zhang, Haiyan Li, Xiaofeng Jiang, Liangqi Cao, Zilong Wen, Xuewei Yang, Ping Xue
BACKGROUND: Cholangiocarcinoma (CCA) is characterized by early lymphatic, metastasis, and low survival rate. Epithelial-mesenchymal transition (EMT) is able to induce tumor metastasis. Although the TGF-β/miR-200 signals promote EMT in various types of cancer, the regulatory mechanism in CCA is still unclear. METHODS: Expression of miR-200b, TGF-β, and EMT markers were measured in tumor samples and cell lines by qRT-PCR and western blot. CCK8 assay was performed to measure the cell viability...
October 30, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29073933/role-of-tumor-suppressor-p53-and-micro-rna-interplay-in-multiple-myeloma-pathogenesis
#5
REVIEW
Jahangir Abdi, Nasrin Rastgoo, Lihong Li, Wenming Chen, Hong Chang
The molecular mechanisms underlying dysregulated wild type (wt) p53 in multiple myeloma (MM) have been subjects of intense investigation for years. Indeed, correlation of rarely occurring TP53 gene mutations or deletions with adverse clinical outcomes in MM patients is strongly established, while in majority of cases wtp53 seems to be non-functional or dysregulated bearing a high clinical impact. Interestingly, findings from recent investigations show that micro-RNAs (miRNAs) may contribute to suppression of wtp53 in MM, as they are now known to function as key regulatory elements in the p53 network...
October 26, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29065888/a-comprehensive-data-mining-study-shows-that-most-nuclear-receptors-act-as-newly-proposed-homeostasis-associated-molecular-pattern-receptors
#6
Luqiao Wang, Gayani Nanayakkara, Qian Yang, Hongmei Tan, Charles Drummer, Yu Sun, Ying Shao, Hangfei Fu, Ramon Cueto, Huimin Shan, Teodoro Bottiglieri, Ya-Feng Li, Candice Johnson, William Y Yang, Fan Yang, Yanjie Xu, Hang Xi, Weiqing Liu, Jun Yu, Eric T Choi, Xiaoshu Cheng, Hong Wang, Xiaofeng Yang
BACKGROUND: Nuclear receptors (NRs) can regulate gene expression; therefore, they are classified as transcription factors. Despite the extensive research carried out on NRs, still several issues including (1) the expression profile of NRs in human tissues, (2) how the NR expression is modulated during atherosclerosis and metabolic diseases, and (3) the overview of the role of NRs in inflammatory conditions are not fully understood. METHODS: To determine whether and how the expression of NRs are regulated in physiological/pathological conditions, we took an experimental database analysis to determine expression of all 48 known NRs in 21 human and 17 murine tissues as well as in pathological conditions...
October 24, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29061113/the-emerging-roles-of-ngs-based-liquid-biopsy-in-non-small-cell-lung-cancer
#7
REVIEW
Yi-Chen Zhang, Qing Zhou, Yi-Long Wu
The treatment paradigm of non-small cell lung cancer (NSCLC) has evolved into oncogene-directed precision medicine. Identifying actionable genomic alterations is the initial step towards precision medicine. An important scientific progress in molecular profiling of NSCLC over the past decade is the shift from the traditional piecemeal fashion to massively parallel sequencing with the use of next-generation sequencing (NGS). Another technical advance is the development of liquid biopsy with great potential in providing a dynamic and comprehensive genomic profiling of NSCLC in a minimally invasive manner...
October 23, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29058636/clinical-trials-of-car-t-cells-in-china
#8
Bingshan Liu, Yongping Song, Delong Liu
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications...
October 23, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29058602/the-crosstalk-between-autophagic-and-endo-exosomal-pathways-in-antigen-processing-for-mhc-presentation-in-anticancer-t-cell-immune-responses
#9
REVIEW
Liangshun You, Liping Mao, Juying Wei, Shenhe Jin, Chunmei Yang, Hui Liu, Li Zhu, Wenbin Qian
T cells recognize antigen fragments from proteolytic products that are presented to them in the form of peptides on major histocompatibility complex (MHC) molecules, which is crucial for the T cell to identify infected or transformed cells. Autophagy, a process that delivers cytoplasmic constituents for lysosomal degradation, has been observed to provide a substantial source of intra- and extracellular antigens for MHC presentation to T cells, which will impact the tumor-specific immune response. Meanwhile, extracellular components are transported to cytoplasm for the degradation/secretion process by the endo-/exosomal pathway and are thus involved in multiple physiological and pathological processes, including immune responses...
October 23, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29041946/the-role-of-b-cell-antigen-receptors-in-mantle-cell-lymphoma
#10
REVIEW
Michael Fichtner, Martin Dreyling, Mascha Binder, Martin Trepel
Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and secondary resistance to currently available therapies in most cases. Therefore, despite recent advances in the treatment of this disease, it is still considered to be incurable in the majority of cases. MCL B cells retain their B cell antigen receptor (BCR) expression during and after neoplastic transformation. BCRs in MCL show distinct patterns of antigen selection and ongoing BCR signaling. However, little is known about the involved antigens and the mechanisms leading to lymphomagenesis and lymphoma progression in MCL...
October 17, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28985760/an-improved-pre-clinical-patient-derived-liquid-xenograft-mouse-model-for-acute-myeloid-leukemia
#11
Zhisheng Her, Kylie Su Mei Yong, Kathirvel Paramasivam, Wilson Wei Sheng Tan, Xue Ying Chan, Sue Yee Tan, Min Liu, Yong Fan, Yeh Ching Linn, Kam Man Hui, Uttam Surana, Qingfeng Chen
BACKGROUND: Xenotransplantation of patient-derived AML (acute myeloid leukemia) cells in NOD-scid Il2rγ (null) (NSG) mice is the method of choice for evaluating this human hematologic malignancy. However, existing models constructed using intravenous injection in adult or newborn NSG mice have inferior engraftment efficiency, poor peripheral blood engraftment, or are difficult to construct. METHODS: Here, we describe an improved AML xenograft model where primary human AML cells were injected into NSG newborn pups intrahepatically...
October 6, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28985758/pharmacological-targeting-of-the-ephrin-receptor-kinase-signalling-by-glpg1790-in-vitro-and-in-vivo-reverts-oncophenotype-induces-myogenic-differentiation-and-radiosensitizes-embryonal-rhabdomyosarcoma-cells
#12
Francesca Megiorni, Giovanni Luca Gravina, Simona Camero, Simona Ceccarelli, Andrea Del Fattore, Vincenzo Desiderio, Federica Papaccio, Heather P McDowell, Rajeev Shukla, Antonio Pizzuti, Filip Beirinckx, Philippe Pujuguet, Laurent Saniere, Ellen Van der Aar, Roberto Maggio, Francesca De Felice, Cinzia Marchese, Carlo Dominici, Vincenzo Tombolini, Claudio Festuccia, Francesco Marampon
BACKGROUND: EPH (erythropoietin-producing hepatocellular) receptors are clinically relevant targets in several malignancies. This report describes the effects of GLPG1790, a new potent pan-EPH inhibitor, in human embryonal rhabdomyosarcoma (ERMS) cell lines. METHODS: EPH-A2 and Ephrin-A1 mRNA expression was quantified by real-time PCR in 14 ERMS tumour samples and in normal skeletal muscle (NSM). GLPG1790 effects were tested in RD and TE671 cell lines, two in vitro models of ERMS, by performing flow cytometry analysis, Western blotting and immunofluorescence experiments...
October 6, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28985752/erratum-to-miip-remodels-rac1-mediated-cytoskeleton-structure-in-suppression-of-endometrial-cancer-metastasis
#13
Yingmei Wang, Limei Hu, Ping Ji, Fei Teng, Wenyan Tian, Yuexin Liu, David Cogdell, Jinsong Liu, Anil K Sood, Russell Broaddus, Fengxia Xue, Wei Zhang
No abstract text is available yet for this article.
October 6, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28982385/erratum-to-interim-analysis-of-survival-in-a-prospective-multi-center-registry-cohort-of-cutaneous-melanoma-tested-with-a-prognostic-31-gene-expression-profile-test
#14
Eddy C Hsueh, James R DeBloom, Jonathan Lee, Jeffrey J Sussman, Kyle R Covington, Brooke Middlebrook, Clare Johnson, Robert W Cook, Craig L Slingluff, Kelly M McMasters
No abstract text is available yet for this article.
October 5, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28974240/association-of-a-novel-point-mutation-in-msh2-gene-with-familial-multiple-primary-cancers
#15
Hai Hu, Hong Li, Feng Jiao, Ting Han, Meng Zhuo, Jiujie Cui, Yixue Li, Liwei Wang
BACKGROUND: Multiple primary cancers (MPC) have been identified as two or more cancers without any subordinate relationship that occur either simultaneously or metachronously in the same or different organs of an individual. Lynch syndrome is an autosomal dominant genetic disorder that increases the risk of many types of cancers. Lynch syndrome patients who suffer more than two cancers can also be considered as MPC; patients of this kind provide unique resources to learn how genetic mutation causes MPC in different tissues...
October 3, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28974232/the-stem-cell-factor-sall4-is-an-essential-transcriptional-regulator-in-mixed-lineage-leukemia-rearranged-leukemogenesis
#16
Lina Yang, Li Liu, Hong Gao, Jaya Pratap Pinnamaneni, Deepthi Sanagasetti, Vivek P Singh, Kai Wang, Megumi Mathison, Qianzi Zhang, Fengju Chen, Qianxing Mo, Todd Rosengart, Jianchang Yang
BACKGROUND: The stem cell factor spalt-like transcription factor 4 (SALL4) plays important roles in normal hematopoiesis and also in leukemogenesis. We previously reported that SALL4 exerts its effect by recruiting important epigenetic factors such as DNA methyltransferases DNMT1 and lysine-specific demethylase 1 (LSD1/KDM1A). Both of these proteins are critically involved in mixed lineage leukemia (MLL)-rearranged (MLL-r) leukemia, which has a very poor clinical prognosis. Recently, SALL4 has been further linked to the functions of MLL and its target gene homeobox A9 (HOXA9)...
October 3, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28969692/role-of-protein-kinases-ck1%C3%AE-and-ck2-in-multiple-myeloma-regulation-of-pivotal-survival-and-stress-managing-pathways
#17
REVIEW
Sabrina Manni, Marilena Carrino, Francesco Piazza
Multiple myeloma (MM) is a malignant tumor of transformed plasma cells. MM pathogenesis is a multistep process. This cancer can occur de novo (rarely) or it can develop from monoclonal gammopathy of undetermined significance (most of the cases). MM can be asymptomatic (smoldering myeloma) or clinically active. Malignant plasma cells exploit intrinsic and extrinsic bone marrow microenvironment-derived growth signals. Upregulation of stress-coping pathways is also instrumental to maintain MM cell growth. The phylogenetically related Ser/Thr kinases CSNK1A1 (CK1α) and CSNK2 (CK2) have recently gained a growing importance in hematologic malignancies arising both from precursors and from mature blood cells...
October 2, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28962635/long-term-survival-in-patients-treated-with-ruxolitinib-for-myelofibrosis-comfort-i-and-ii-pooled-analyses
#18
Srdan Verstovsek, Jason Gotlib, Ruben A Mesa, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N Harrison, Ronald Paquette, William Sun, Ahmad Naim, Peter Langmuir, Tuochuan Dong, Prashanth Gopalakrishna, Vikas Gupta
BACKGROUND: Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in patients with intermediate-2 (int-2) or high-risk MF. METHODS: This was an exploratory analysis of 5-year data pooled from the phase 3 COMFORT-I and -II trials. In both trials, patients could cross over to ruxolitinib from the control group (COMFORT-I, placebo; COMFORT-II, best available therapy)...
September 29, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28931402/recent-advances-of-bispecific-antibodies-in-solid-tumors
#19
REVIEW
Shengnan Yu, Anping Li, Qian Liu, Xun Yuan, Hanxiao Xu, Dechao Jiao, Richard G Pestell, Xinwei Han, Kongming Wu
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attracting more and more attention as a novel strategy of antitumor immunotherapy. BsAb not only offers an effective linkage between therapeutics (e.g., immune effector cells, radionuclides) and targets (e.g., tumor cells) but also simultaneously blocks two different oncogenic mediators. In recent decades, a variety of BsAb formats have been generated...
September 20, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28923081/erratum-to-romidepsin-for-the-treatment-of-relapsed-refractory-peripheral-t-cell-lymphoma-prolonged-stable-disease-provides-clinical-benefits-for-patients-in-the-pivotal-trial
#20
Francine Foss, Steven Horwitz, Barbara Pro, H Miles Prince, Lubomir Sokol, Barbara Balser, Julie Wolfson, Bertrand Coiffier
No abstract text is available yet for this article.
September 18, 2017: Journal of Hematology & Oncology
journal
journal
41912
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"